Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial
Renato D. Lópes, Pedro Gabriel Melo de Barros e Silva, Remo H.M. Furtado, et al.
The Lancet (2021) Vol. 397, Iss. 10291, pp. 2253-2263
Open Access | Times Cited: 448

Showing 26-50 of 448 citing articles:

Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials
Luis Ortega‐Paz, Mattía Galli, Davide Capodanno, et al.
European Heart Journal - Cardiovascular Pharmacotherapy (2021) Vol. 8, Iss. 7, pp. 677-686
Open Access | Times Cited: 65
Anticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients With COVID-19: COVID-PACT
Erin A. Bohula, David D. Berg, Mathew S. Lopes, et al.
Circulation (2022) Vol. 146, Iss. 18, pp. 1344-1356
Open Access | Times Cited: 65
Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper
Thomas Marjot, Christiane S. Eberhardt, Tobias Boettler, et al.
Journal of Hepatology (2022) Vol. 77, Iss. 4, pp. 1161-1197
Open Access | Times Cited: 62
Long-term kidney function recovery and mortality after COVID-19-associated acute kidney injury: an international multi-centre observational cohort study
Byorn W.L. Tan, Bryce W. Q. Tan, Amelia L.M. Tan, et al.
EClinicalMedicine (2022) Vol. 55, pp. 101724-101724
Open Access | Times Cited: 61
American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients
Adam Cuker, Eric Tseng, Robby Nieuwlaat, et al.
Blood Advances (2021) Vol. 5, Iss. 20, pp. 3951-3959
Open Access | Times Cited: 58
American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients
Adam Cuker, Eric Tseng, Robby Nieuwlaat, et al.
Blood Advances (2022) Vol. 6, Iss. 17, pp. 4915-4923
Open Access | Times Cited: 56
Coagulation factors directly cleave SARS-CoV-2 spike and enhance viral entry
Edward R. Kastenhuber, Marisa Mercadante, Benjamin E. Nilsson-Payant, et al.
eLife (2022) Vol. 11
Open Access | Times Cited: 55
Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: updated clinical guidance from the anticoagulation forum
Geoffrey D. Barnes, Allison Burnett, Arthur L. Allen, et al.
Journal of Thrombosis and Thrombolysis (2022) Vol. 54, Iss. 2, pp. 197-210
Open Access | Times Cited: 54
Anticoagulation in Patients With COVID-19
Michael E. Farkouh, Gregg W. Stone, Anuradha Lala, et al.
Journal of the American College of Cardiology (2022) Vol. 79, Iss. 9, pp. 917-928
Open Access | Times Cited: 51
Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial
Frank Cools, Saverio Virdone, J.P.S. Sawhney, et al.
The Lancet Haematology (2022) Vol. 9, Iss. 8, pp. e594-e604
Open Access | Times Cited: 51
Anticoagulants for people hospitalised with COVID-19
Ronald Luiz Gomes Flumignan, Vinicius Tassoni Civile, Jéssica Dantas de Sá Tinôco, et al.
Cochrane library (2022) Vol. 2022, Iss. 3
Open Access | Times Cited: 50
Pathophysiological mechanisms of thrombosis in acute and long COVID-19
Haijiao Jing, Xiaoming Wu, Mengqi Xiang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 49
Clinical features of thrombosis and bleeding in COVID-19
Mari R. Thomas, Marie Scully
Blood (2022) Vol. 140, Iss. 3, pp. 184-195
Open Access | Times Cited: 41
The intersection of obesity and (long) COVID-19: Hypoxia, thrombotic inflammation, and vascular endothelial injury
Mengqi Xiang, Xiaoming Wu, Haijiao Jing, et al.
Frontiers in Cardiovascular Medicine (2023) Vol. 10
Open Access | Times Cited: 38
Association between acute disease severity and one-year quality of life among post-hospitalisation COVID-19 patients: Coalition VII prospective cohort study
Régis Goulart Rosa, Alexandre Biasi Cavalcanti, Luciano César Pontes Azevedo, et al.
Intensive Care Medicine (2023) Vol. 49, Iss. 2, pp. 166-177
Open Access | Times Cited: 37
Effects of Standard-Dose Prophylactic, High-Dose Prophylactic, and Therapeutic Anticoagulation in Patients With Hypoxemic COVID-19 Pneumonia
Vincent Labbé, Damien Contou, Nicholas Heming, et al.
JAMA Internal Medicine (2023) Vol. 183, Iss. 6, pp. 520-520
Open Access | Times Cited: 21
Impact of vaccination on the association of COVID-19 with cardiovascular diseases: An OpenSAFELY cohort study
Geneviève Cézard, Rachel Denholm, Rosemary Knight, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 13
Effectiveness of Drug Repurposing and Natural Products Against SARS-CoV-2: A Comprehensive Review
Paula Andrea Cuartas Velásquez, Juan C. Hernández, Elkin Galeano, et al.
Clinical Pharmacology Advances and Applications (2024) Vol. Volume 16, pp. 1-25
Open Access | Times Cited: 10
Appropriate thromboprophylaxis strategy for COVID-19 patients on dosage, antiplatelet therapy, outpatient and post-discharge prophylaxis: a meta-analysis of randomized controlled trials
Jiahao Meng, Hang Tang, Yifan Xiao, et al.
International Journal of Surgery (2024)
Open Access | Times Cited: 8
Therapeutic versus Prophylactic Bemiparin in Hospitalized Patients with Nonsevere COVID-19 Pneumonia (BEMICOP Study): An Open-Label, Multicenter, Randomized, Controlled Trial
María Marcos‐Jubilar, Francisco Carmona-Torre, Rosa Vidal, et al.
Thrombosis and Haemostasis (2021) Vol. 122, Iss. 02, pp. 295-299
Open Access | Times Cited: 52
Prevention and management of thrombosis in hospitalised patients with COVID-19 pneumonia
Jean‐Louis Vincent, Marcel Levi, Beverley J. Hunt
The Lancet Respiratory Medicine (2021) Vol. 10, Iss. 2, pp. 214-220
Open Access | Times Cited: 44
Randomized trials of therapeutic heparin for COVID‐19: A meta‐analysis
Michelle Sholzberg, Bruno R. da Costa, Grace H. Tang, et al.
Research and Practice in Thrombosis and Haemostasis (2021) Vol. 5, Iss. 8, pp. e12638-e12638
Open Access | Times Cited: 44
Randomized Study of Rivaroxaban vs Placebo on Disease Progression and Symptoms Resolution in High-Risk Adults With Mild Coronavirus Disease 2019
Jintanat Ananworanich, Robin Mogg, Michael Dunne, et al.
Clinical Infectious Diseases (2021) Vol. 75, Iss. 1, pp. e473-e481
Open Access | Times Cited: 43
TEG®, Microclot and Platelet Mapping for Guiding Early Management of Severe COVID-19 Coagulopathy
Gert Jacobus Laubscher, Petrus Johannes Lourens, Chantelle Venter, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 22, pp. 5381-5381
Open Access | Times Cited: 43
The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune thrombotic thrombocytopenia
Toshiaki Iba, Jerrold H. Levy
Trends in Cardiovascular Medicine (2021) Vol. 32, Iss. 1, pp. 1-9
Open Access | Times Cited: 41

Scroll to top